MétaCan
Menu
Back to cohort

Abstract 13520: Empagliflozin Reduces Markers of Arterial Stiffness, Vascular Resistance and Cardiac Workload in EMPA-REG OUTCOME

2016· article· en· W2904072698 on OpenAlexaff
Robert Ćhilton, Lars Gullestad, David Fitchett, Silvio E. Inzucchi, Michaela Mattheus, Hans J. Woerle, Odd Erik Johansen

Bibliographic record

VenueCirculation · 2016
Typearticle
Languageen
FieldMedicine
TopicCardiovascular Function and Risk Factors
Canadian institutionsSt. Michael's Hospital
Fundersnot available
KeywordsEmpagliflozinMedicineArterial stiffnessEMPACardiologyInternal medicineVascular resistanceType 2 diabetesDiabetes mellitusBlood pressureHemodynamicsEndocrinology

Abstract

fetched live from OpenAlex

Introduction: In EMPA-REG OUTCOME ® , empagliflozin added to standard of care in patients with type 2 diabetes and established vascular disease, significantly reduced the primary composite outcome of CV death, non-fatal myocardial infarction or non-fatal stroke, a result driven mainly by a 38% reduction in CV death. We aimed to assess the vascular effects of empagliflozin in the trial, beyond its recognized effects in reducing systolic blood pressure (SBP) and diastolic BP (DBP). Hypothesis: We hypothesized that empagliflozin reduced 1) pulse pressure (PP), a vascular marker of arterial stiffness determined by the cardiac output, the stiffness of elastic central arteries and wave reflection (PP = SBP - DBP), 2) mean arterial pressure (MAP), a measure reflecting the cardiac cycle determined by the cardiac output, systemic vascular resistance, and central venous pressure (MAP = ([2 x diastolic BP]+ systolic BP)/3), and 3) the double product (DP), a marker of cardiac workload and an indirect measure of myocardial oxygen demand (DP = heart rate x SBP). Methods: Patients with type 2 diabetes and high CV risk were randomised to receive placebo, empagliflozin 10 mg, or empagliflozin 25 mg in addition to standard of care. We analysed changes from baseline to week 164 for SBP, DBP, HR, PP, MAP and DP, between treatment and placebo groups using a mixed model repeated measures analysis. Results: In total, 2333, 2345 and 2342 patients received placebo, empagliflozin 10 mg and empagliflozin 25 mg, respectively and followed for a median period of 3.1 years. There were nominal significantly greater reductions in PP, MAP and DP with empagliflozin treatment as compared with placebo (Table), without increases in mean HR (Table). Conclusions: Empagliflozin had favorable effects on BP, arterial stiffness, vascular resistance and on the indirect measure of cardiac workload. Further analyses are needed to determine the potential contribution of these changes to the reduction in CV mortality.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.018

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0050.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.017
GPT teacher head0.253
Teacher spread0.237 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations9
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueCirculationSame topicCardiovascular Function and Risk FactorsFrench-language works237,207